◎ Sugi Atlas

Atlas / Drug / Infigratinib

Infigratinib

drug
On this page

Also known as Bgj-398BGJ398MVP-BGJ398NVP-BGJ398BGJ398 (NVP-BGJ398|INFIGRATINIB)BGJ398 (NVP-BGJ398)INFIGRATINIB (BGJ398)

Summary

Infigratinib (CHEMBL1852688) is an approved small-molecule fibroblast growth factor receptor antagonist (ATC L01EN03) targeting FGFR1, FGFR2, and FGFR3; indicated across 15 conditions including neoplasm and cholangiocarcinoma; with CIViC clinical evidence for 25 variant-indication associations (e.g. FGFR2::v Fusion OR FGFR2::? Fusion in cholangiocarcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EN03
  • Targets: 5 (FGFR1, FGFR2, FGFR3…)
  • Indications: 15 conditions
  • Clinical trials: 28
  • Precision-oncology evidence (CIViC): 25 variant–indication associations
  • Chemistry: 560.5 Da · C26H31Cl2N7O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1852688
NameInfigratinib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID53235510
ChEBICHEBI:63451
ATCL01EN03
Molecular formulaC26H31Cl2N7O3
Molecular weight560.5
InChIKeyQADPYRIHXKWUSV-UHFFFAOYSA-N

SMILES: CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl

IUPAC name: 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea

ChEBI definition: A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor.

Pharmacological roles (ChEBI): fibroblast growth factor receptor antagonist, antineoplastic agent.

Also known as: Bgj-398, BGJ-398, BGJ398, Infigratinib, MVP-BGJ398, NVP-BGJ398, BGJ398 (NVP-BGJ398|INFIGRATINIB), BGJ398 (NVP-BGJ398), INFIGRATINIB, INFIGRATINIB (BGJ398)

Parent form; salt/anhydrous children: CHEMBL1834657

Patent coverage: 794 distinct patent families (2,209 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
FGFR1fibroblast growth factor receptor 1Inhibition9.0511.5%P11362
FGFR2fibroblast growth factor receptor 2Inhibition8.851.7%P21802
FGFR3fibroblast growth factor receptor 3Inhibition90.5%P22607
FGFR4fibroblast growth factor receptor 4Inhibition7.220.7%P22455
KDRkinase insert domain receptorInhibition6.741.1%P35968

Broader ChEMBL bioactivity targets: 33 (assay-derived). Sample: Tyrosine-protein kinase Fyn, Tyrosine-protein kinase ABL1, Vascular endothelial growth factor receptor 1, Mast/stem cell growth factor receptor Kit, Vascular endothelial growth factor receptor 3, Receptor-type tyrosine-protein kinase FLT3, Insulin receptor, Platelet-derived growth factor receptor alpha, Proto-oncogene tyrosine-protein kinase receptor Ret, Tyrosine-protein kinase Yes.

Bioactivity

ChEMBL activities: 130 potent at pChembl ≥ 5 of 131 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
FGFR29.34IC500.46nMCHEMBL_ACT_29151883
FGFR19.23IC500.59nMCHEMBL_ACT_19319733
FGFR39.18IC500.66nMCHEMBL_ACT_24805364
FGFR29.17IC500.68nMCHEMBL_ACT_24805441
FGFR39.17IC500.68nMCHEMBL_ACT_29152170
FGFR39.15IC500.7nMCHEMBL_ACT_25755671
FGFR19.15IC500.7nMCHEMBL_ACT_25786825
FGFR19.15IC500.7nMCHEMBL_ACT_29164274
FGFR29.14IC500.72nMCHEMBL_ACT_29152152
FGFR19.1IC500.8nMCHEMBL_ACT_18745418
FGFR49.09IC500.82nMCHEMBL_ACT_18745379
FGFR19.05IC500.9nMCHEMBL_ACT_23284801
FGFR19.05IC500.9nMCHEMBL_ACT_25755819
FGFR19.05IC500.9nMCHEMBL_ACT_25786826
FGFR19.05IC500.9nMCHEMBL_ACT_29152319
FGFR19IC501nMCHEMBL_ACT_17795204
FGFR39IC501nMCHEMBL_ACT_17979922
FGFR29IC501nMCHEMBL_ACT_17979923
FGFR19IC501nMCHEMBL_ACT_17979924
FGFR39IC501nMCHEMBL_ACT_23284809
FGFR39IC501nMCHEMBL_ACT_25755821
FGFR39IC501nMCHEMBL_ACT_25786834
FGFR19IC501nMCHEMBL_ACT_27244235
FGFR19IC501nMCHEMBL_ACT_28240961
FGFR39IC501nMCHEMBL_ACT_29152335
FGFR28.92IC501.2nMCHEMBL_ACT_18745409
FGFR28.85IC501.4nMCHEMBL_ACT_23284805
FGFR28.85IC501.4nMCHEMBL_ACT_25755820
FGFR28.85IC501.4nMCHEMBL_ACT_25786830
FGFR28.85IC501.4nMCHEMBL_ACT_29152327

Target pathways

Aggregated over 5 target gene(s): FGFR1, FGFR2, FGFR3, FGFR4, KDR.

Top Reactome pathways

62 total, by targets touching each:

PathwayTargetsGenes
PI3K Cascade4FGFR1, FGFR2, FGFR3, FGFR4
PIP3 activates AKT signaling4FGFR1, FGFR2, FGFR3, FGFR4
Constitutive Signaling by Aberrant PI3K in Cancer4FGFR1, FGFR2, FGFR3, FGFR4
RAF/MAP kinase cascade4FGFR1, FGFR2, FGFR3, FGFR4
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling4FGFR1, FGFR2, FGFR3, FGFR4
betaKlotho-mediated ligand binding1FGFR4
Signaling by FGFR1 amplification mutants1FGFR1
Signaling by activated point mutants of FGFR11FGFR1
FGFR4 mutant receptor activation1FGFR4
Signaling by activated point mutants of FGFR31FGFR3
FGFR4 ligand binding and activation1FGFR4
FGFR1b ligand binding and activation1FGFR1
FGFR3b ligand binding and activation1FGFR3
FGFR3c ligand binding and activation1FGFR3
FGFR1c ligand binding and activation1FGFR1
FGFR1c and Klotho ligand binding and activation1FGFR1
FGFR2c ligand binding and activation1FGFR2
FGFR2b ligand binding and activation1FGFR2
Neuropilin interactions with VEGF and VEGFR1KDR
VEGF binds to VEGFR leading to receptor dimerization1KDR
Signaling by FGFR2 amplification mutants1FGFR2
t(4;14) translocations of FGFR31FGFR3
Activated point mutants of FGFR21FGFR2
Integrin cell surface interactions1KDR
NCAM signaling for neurite out-growth1FGFR1
VEGFA-VEGFR2 Pathway1KDR
Signal transduction by L11FGFR1
VEGFR2 mediated cell proliferation1KDR
Phospholipase C-mediated cascade: FGFR11FGFR1
Phospholipase C-mediated cascade; FGFR21FGFR2

Dominant GO biological processes

GO termTargets
protein phosphorylation5
positive regulation of cell population proliferation5
positive regulation of MAPK cascade5
fibroblast growth factor receptor signaling pathway4
peptidyl-tyrosine phosphorylation4
protein autophosphorylation4
positive regulation of ERK1 and ERK2 cascade4
angiogenesis3
positive regulation of mesenchymal cell proliferation3
positive regulation of phospholipase activity3
cell migration3
skeletal system morphogenesis3
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction3
positive regulation of cell communication3
positive regulation of signaling3

Indications & clinical

Indications

15 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
cholangiocarcinoma3MONDO:0019087EFO:0005221
glioblastoma2MONDO:0018177EFO:0000519
melanoma2MONDO:0005105EFO:0000756
osteomalacia2MONDO:0001068EFO:1002027
human papilloma virus infection2MONDO:0005161EFO:0001668
achondroplasia2MONDO:0007037MONDO:0007037
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
paraganglioma2MONDO:0000448EFO:1000453
cervical carcinoma1MONDO:0005131EFO:0001061
breast neoplasm1MONDO:0021100MONDO:0007254
gastrointestinal stromal tumor1MONDO:0011719MONDO:0011719

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 28.

Phase distribution

PhaseTrials
PHASE212
PHASE17
PHASE33
PHASE1/PHASE23
PHASE2/PHASE31
EARLY_PHASE11
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06873035PHASE2/PHASE3ENROLLING_BY_INVITATIONAn Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT03773302PHASE3TERMINATEDPhase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
NCT04197986PHASE3TERMINATEDOral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
NCT06164951PHASE3COMPLETEDA Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
NCT05145010PHASE2ENROLLING_BY_INVITATIONExtension Study of Infigratinib in Children With Achondroplasia (ACH)
NCT07393373PHASE2ENROLLING_BY_INVITATIONOpen-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
NCT01975701PHASE2COMPLETEDA Phase 2 Study of BGJ398 in Patients With Recurrent GBM
NCT02150967PHASE2TERMINATEDA Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
NCT02159066PHASE2COMPLETEDLGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
NCT02160041PHASE2TERMINATEDBGJ398 for Patients With Tumors With FGFR Genetic Alterations
NCT02257541PHASE1/PHASE2COMPLETEDBGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
NCT02706691PHASE2TERMINATEDBGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
NCT03510455PHASE2TERMINATEDBGJ398 for the Treatment of Tumor-Induced Osteomalacia
NCT04228042PHASE1/PHASE2TERMINATEDInfigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
NCT04233567PHASE2COMPLETEDInfigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
NCT04265651PHASE2COMPLETEDStudy of Infigratinib in Children With Achondroplasia
NCT05019794PHASE2UNKNOWNInfigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
NCT05222165PHASE1/PHASE2WITHDRAWNStudy With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
NCT06206278PHASE2TERMINATEDEvaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
NCT01004224PHASE1COMPLETEDA Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
NCT01697605PHASE1COMPLETEDA Phase I Study of Oral BGJ398 in Asian Patients
NCT01928459PHASE1COMPLETEDPhase 1b Trial of BGJ398/BYL719 in Solid Tumors
NCT02312804PHASE1WITHDRAWNPh Ib/BGJ398/Cervix and Other Solid Tumors
NCT04504331PHASE1TERMINATEDStudy of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
NCT04972253PHASE1WITHDRAWNPhase I BLASST-3 Trial
NCT05510427PHASE1WITHDRAWNPhase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
NCT04424966EARLY_PHASE1TERMINATEDInfigratinib in Recurrent High-Grade Glioma Patients
NCT02657486Not specifiedCOMPLETEDBGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Clinical evidence (CIViC)

Variant × indication × effect (25 predictive associations from 29 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
FGFR2::v Fusion OR FGFR2::? FusionCholangiocarcinomaSensitivity/ResponseInfigratinibCIViC AEID11230 +2
FGFR2 MutationCholangiocarcinomaSensitivity/ResponseInfigratinibCIViC BEID5912 +1
FGFR1 AmplificationLung Squamous Cell CarcinomaSensitivity/ResponseInfigratinibCIViC BEID1908
FGFR3 G370CTransitional Cell CarcinomaSensitivity/ResponseInfigratinibCIViC BEID6414
FGFR3 MutationBladder CarcinomaSensitivity/ResponseInfigratinibCIViC BEID1910
FGFR3 R248CTransitional Cell CarcinomaSensitivity/ResponseInfigratinibCIViC BEID6410
FGFR3 R248CBladder CarcinomaSensitivity/ResponseInfigratinibCIViC BEID8318
FGFR3 S249CTransitional Cell CarcinomaSensitivity/ResponseInfigratinibCIViC BEID6404
FGFR1 AmplificationBreast CancerResistanceInfigratinibCIViC BEID1909
FGFR3 Y373CTransitional Cell CarcinomaSensitivity/ResponseInfigratinibCIViC CEID6411 +1
FGFR1 AmplificationBladder CarcinomaSensitivity/ResponseInfigratinibCIViC CEID1911
FGFR3 F384LTransitional Cell CarcinomaSensitivity/ResponseInfigratinibCIViC CEID6415
FGFR3 G380RTransitional Cell CarcinomaSensitivity/ResponseInfigratinibCIViC CEID6413
FGFR3::TACC3 FusionTransitional Cell CarcinomaSensitivity/ResponseInfigratinibCIViC CEID6409
FGFR3 L608VTransitional Cell CarcinomaResistanceInfigratinibCIViC CEID6407
FGFR3 V555LTransitional Cell CarcinomaResistanceInfigratinibCIViC CEID6405
FGFR3 V555MTransitional Cell CarcinomaResistanceInfigratinibCIViC CEID6406
FGFR1 ExpressionSarcomaSensitivity/ResponseFexagratinib + FGF/VEGF Receptor Tyrosine Kinase Inhibitor + PD173074 + InfigratinibCIViC DEID2915
FGFR1 ExpressionHead And Neck Squamous Cell CarcinomaSensitivity/ResponseInfigratinibCIViC DEID799
FGFR1 ExpressionGastric AdenocarcinomaSensitivity/ResponseInfigratinibCIViC DEID800
FGFR1 ExpressionColorectal CancerSensitivity/ResponseInfigratinibCIViC DEID896
FGFR2::AHCYL1 FusionCholangiocarcinomaSensitivity/ResponseInfigratinib + PD173074CIViC DEID1853
FGFR2::BICC1 FusionCholangiocarcinomaSensitivity/ResponseInfigratinib + PD173074CIViC DEID1851
FGFR3 G691RLung AdenocarcinomaSensitivity/ResponseInfigratinib + PD173074CIViC DEID4870
FGFR3 S249CLung AdenocarcinomaSensitivity/ResponseInfigratinib + PD173074CIViC DEID4871

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

190 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CrizotinibChEMBL + PubChemPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
GefitinibChEMBL + PubChemPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
PAZOPANIBChEMBL + PubChemPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
BRIGATINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
ERDAFITINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
FEDRATINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
FUTIBATINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
LENVATINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
NINTEDANIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
NINTEDANIB ESYLATEChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
PONATINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
SUNITINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
VANDETANIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4, KDR
BRIVANIBChEMBLPhase 3FGFR1, FGFR2, FGFR3, FGFR4, KDR
CEDIRANIBChEMBLPhase 3FGFR1, FGFR2, FGFR3, FGFR4, KDR
DOVITINIBChEMBLPhase 3FGFR1, FGFR2, FGFR3, FGFR4, KDR
LESTAURTINIBChEMBLPhase 3FGFR1, FGFR2, FGFR3, FGFR4, KDR
LINIFANIBChEMBLPhase 3FGFR1, FGFR2, FGFR3, FGFR4, KDR
SEMAXANIBChEMBLPhase 3FGFR1, FGFR2, FGFR3, FGFR4, KDR
FEXAGRATINIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4, KDR
FGFR INHIBITOR DEBIO 1347ChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4, KDR
OSI-632ChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4, KDR
R-406ChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4, KDR
REBASTINIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4, KDR
SU-014813ChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4, KDR
TANDUTINIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4, KDR
TOZASERTIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4, KDR
AfatinibPubChemApprovedFGFR1, FGFR2, FGFR3, FGFR4, KDR
SelumetinibPubChemApprovedFGFR1, FGFR2, FGFR3, FGFR4, KDR
AXITINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, KDR
CERITINIBChEMBLPhase 4 (approved)FGFR2, FGFR3, FGFR4, KDR
DASATINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, KDR
MIDOSTAURINChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, KDR
PEMIGATINIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, FGFR4
SORAFENIBChEMBLPhase 4 (approved)FGFR1, FGFR2, FGFR3, KDR
AT-9283ChEMBLPhase 2FGFR1, FGFR2, FGFR3, KDR
DORAMAPIMODChEMBLPhase 2FGFR1, FGFR2, FGFR4, KDR
E-7090ChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4
FISOGATINIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4
FORETINIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, KDR
LIRAFUGRATINIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4
LUCITANIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, KDR
MK-2461ChEMBLPhase 2FGFR1, FGFR2, FGFR3, KDR
RESIGRATINIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4
SEGIGRATINIBChEMBLPhase 2FGFR1, FGFR2, FGFR3, FGFR4
IdelalisibPubChemApprovedFGFR1, FGFR2, FGFR3, FGFR4
ENTRECTINIBChEMBLPhase 4 (approved)FGFR1, FGFR3, KDR
ALISERTIBChEMBLPhase 3FGFR1, FGFR3, KDR
MOTESANIBChEMBLPhase 3FGFR1, FGFR4, KDR
BMS-754807ChEMBLPhase 2FGFR1, FGFR2, FGFR3
CENISERTIBChEMBLPhase 2FGFR1, FGFR3, KDR
CEP-11981ChEMBLPhase 2FGFR1, FGFR3, KDR
DERAZANTINIBChEMBLPhase 2FGFR1, FGFR2, FGFR3
ILORASERTIBChEMBLPhase 2FGFR1, FGFR3, KDR
ROGARATINIBChEMBLPhase 2FGFR1, FGFR3, FGFR4
RX-518ChEMBLPhase 2FGFR1, FGFR2, KDR
REGORAFENIBChEMBL + PubChemPhase 4 (approved)FGFR1, KDR
CABOZANTINIBChEMBLPhase 4 (approved)FGFR1, KDR
ERLOTINIBChEMBLPhase 4 (approved)FGFR2, KDR
IBRUTINIBChEMBLPhase 4 (approved)FGFR2, KDR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot